Antibody to CCDC104 is associated with a paraneoplastic antibody to CDR2 (anti-Yo)
- PMID: 19680650
- PMCID: PMC11031010
- DOI: 10.1007/s00262-009-0742-3
Antibody to CCDC104 is associated with a paraneoplastic antibody to CDR2 (anti-Yo)
Abstract
Patients with cancer may develop paraneoplastic neurological syndromes (PNS) in which onconeural antibodies are important diagnostic findings. As the functional role of onconeural antibodies is largely unknown, insight gained by identifying associated antibodies may help to clarify the pathogenesis of the PNS. In this study, we identified patients with Yo antibodies who also had antibodies to an uncharacterized protein called coiled-coil domain-containing protein 104 (CCDC104). We found a significant association between CCDC104 and Yo antibodies (4 of 38, 10.5%), but not other onconeural antibodies (0 of 158) (P = 0.007, Fisher's exact test). The prevalence of CCDC104 antibodies was approximately similar in patients with cancer (8 of 756, 1.1%) and in healthy blood donors (2 of 300, 0.7%). CCDC104 antibodies were not associated with PNS, as this was found in only two of the ten CCDC104-positive patients. The CCDC104 protein, whose function is unknown, is expressed in various human tissues, including the brain, and is localized mainly to the nucleus, but is also found in the cytoplasm. The association between Yo and CCDC104 antibodies may indicate functional similarities.
Figures



Similar articles
-
"Non-classical" paraneoplastic neurological syndromes associated with well-characterized antineuronal antibodies as compared to "classical" syndromes - More frequent than expected.J Neurol Sci. 2015 May 15;352(1-2):58-61. doi: 10.1016/j.jns.2015.03.027. Epub 2015 Mar 23. J Neurol Sci. 2015. PMID: 25824848
-
Multiplex serology of paraneoplastic antineuronal antibodies.J Immunol Methods. 2013 May 31;391(1-2):125-32. doi: 10.1016/j.jim.2013.02.017. Epub 2013 Mar 13. J Immunol Methods. 2013. PMID: 23500780
-
Onconeural antibodies in patients with neurological symptoms: detection and clinical significance.Acta Neurol Scand Suppl. 2011;(191):83-8. doi: 10.1111/j.1600-0404.2011.01549.x. Acta Neurol Scand Suppl. 2011. PMID: 21711262 Review.
-
Hu and Yo antibodies have heterogeneous avidity.J Neuroimmunol. 2007 Apr;185(1-2):162-7. doi: 10.1016/j.jneuroim.2007.01.016. Epub 2007 Mar 2. J Neuroimmunol. 2007. PMID: 17336396
-
Paraneoplastic neurological syndromes associated with Yo, Hu, and Ri autoantibodies.Clin Rev Allergy Immunol. 2000 Aug;19(1):19-29. doi: 10.1385/CRIAI:19:1:19. Clin Rev Allergy Immunol. 2000. PMID: 11064823 Review. No abstract available.
Cited by
-
CDR2 antigen and Yo antibodies.Cancer Immunol Immunother. 2011 Feb;60(2):283-9. doi: 10.1007/s00262-010-0943-9. Epub 2010 Nov 16. Cancer Immunol Immunother. 2011. PMID: 21080165 Free PMC article.
-
'Medusa head ataxia': the expanding spectrum of Purkinje cell antibodies in autoimmune cerebellar ataxia. Part 3: Anti-Yo/CDR2, anti-Nb/AP3B2, PCA-2, anti-Tr/DNER, other antibodies, diagnostic pitfalls, summary and outlook.J Neuroinflammation. 2015 Sep 17;12:168. doi: 10.1186/s12974-015-0358-9. J Neuroinflammation. 2015. PMID: 26377319 Free PMC article. Review.
References
-
- Graus F, Delattre JY, Antoine JC, Dalmau J, Giometto B, Grisold W, Honnorat J, Smitt PS, Vedeler C, Verschuuren JJ, Vincent A, Voltz R. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry. 2004;75:1135–1140. doi: 10.1136/jnnp.2003.034447. - DOI - PMC - PubMed
-
- Knudsen A, Monstad SE, Dorum A, Lonning PE, Salvesen HB, Drivsholm L, Aarseth JH, Vedeler CA. Ri antibodies in patients with breast, ovarian or small cell lung cancer determined by a sensitive immunoprecipitation technique. Cancer Immunol Immunother. 2006;55:1280–1284. doi: 10.1007/s00262-006-0121-2. - DOI - PMC - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
Research Materials